Company
Kyverna Therapeutics
We Develop Life Changing Medicines for Patients Living With Autoimmune Diseases
Also known as Kyverna, Kyverna Therapeutics, Inc.
- Business model
- B2B
- Customers
- Patients Living With Autoimmune Diseases
- Legal name
- Kyverna Therapeutics, Inc.
- kyvernatx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Kyverna is pioneering a durable disease-clearing approach aiming for deep B cell depletion, an immune system reset, and long-term remission in autoimmune diseases. We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.
Funding snapshot
- Total raised
- $152MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $152M2021-11-09
Funding rounds
- Round, 2021
- $152M2021-11-09, SEC form D sold, 24 investors
Loading relationship preview